{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:38:51Z","timestamp":1790667531215,"version":"4.1.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008057","name":"Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Universitari La Fe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The aim of the study is to assess phenotypic imaging patterns and the response to treatment with [<jats:sup>177<\/jats:sup>Lu]Lu-DOTA-TATE and\/or [<jats:sup>131<\/jats:sup>I]MIBG in paragangliomas (PGLs) and pheochromocytomas (PHEOs), globally and according to the primary location.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a 17-patient retrospective observational study, with 9 cases treated with [<jats:sup>177<\/jats:sup>Lu]Lu-DOTA-TATE and 8 with [<jats:sup>131<\/jats:sup>I]MIBG (37 total treatments). Functional imaging scans and treatment responses were studied in order to choose the best therapeutic option and to define the progression-free survival (PFS) and disease control rate (DCR) according to treatment modality and primary location.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All patients were studied with phenotypic nuclear medicine images. Twelve of 17 patients were tested with both [<jats:sup>123<\/jats:sup>I]MIBG and somatostatin receptor images, and 6\/12 showed appropriate expression of both targets to treatment in the phenotypic images. The rest of the patients were tested with one of the image modalities or only showed suitable uptake of a single radiotracer and were treated with the corresponding therapeutic option. [<jats:sup>177<\/jats:sup>Lu]Lu-DOTA-TATE PFS was 29 months with a DCR of 88.8%. [<jats:sup>131<\/jats:sup>I]MIBG PFS was 18.5 months with a 62.5% DCR. According to the primary location, the best PFS was in PHEOs treated with [<jats:sup>177<\/jats:sup>Lu]Lu-DOTA-TATE. Although the series are small due to the low disease prevalence and do not allow to yield statistically significant differences, this first study comparing [<jats:sup>177<\/jats:sup>Lu]Lu-DOTA-TATE and [<jats:sup>131<\/jats:sup>I]MIBG displays a trend to an overall longer PFS with [<jats:sup>177<\/jats:sup>Lu]Lu-DOTA-TATE, especially in the adrenal primary location. When both radionuclide targets are expressed, the patients\u2019 comorbidity and treatment effectiveness should be valued together with the intensity uptake in the phenotypic image in order to choose the best therapeutic option. These preliminary retrospective results reinforce the need for a prospective, multicentric trial to be confirmed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.778322","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T05:45:11Z","timestamp":1644212711000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["[177Lu]Lu-DOTA-TATE and [131I]MIBG Phenotypic Imaging-Based Therapy in Metastatic\/Inoperable Pheochromocytomas and Paragangliomas: Comparative Results in a Single Center"],"prefix":"10.3389","volume":"13","author":[{"given":"Stefan","family":"Prado-Wohlwend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"del Olmo-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Bello-Arques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Francisco","family":"Merino-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and Paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"New N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/er.2017-00062","article-title":"New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification","volume":"38","author":"Crona","year":"2017","journal-title":"Endocr Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3703","article-title":"High-Specific-Activity 131I-MIBG vs 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma","volume":"27","author":"Jha","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for Radionuclide Imaging of Phaeochromocytoma and Paraganglioma","volume":"46","author":"Taieb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/61\/13\/R150","article-title":"Applications and Limitations of Radiomics","volume":"61","author":"Yip","year":"2016","journal-title":"Phys Med Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2008","journal-title":"Eur J Cancer (1990)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"EANM, and SNMMI Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) in Neuroendocrine Tumours","volume":"40","author":"Zaknun","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0715-3","article-title":"EANM Procedure Guidelines for 131I-Meta-Iodobenzylguanidine (131I-mIBG) Therapy","volume":"35","author":"Giammarile","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.158808","article-title":"18f-FDG PET\/CT and PET\/MRI Perform Equally Well in Cancer: Evidence From Studies on More Than 2,300 Patients","volume":"57","author":"Spick","year":"2016","journal-title":"J Nucl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101505","article-title":"Current Management of Pheochromocytoma\/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine","volume":"11","author":"N\u00f6lting","year":"2019","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2215-8","article-title":"EANM 2012 Guidelines for Radionuclide Imaging of Phaeochromocytoma and Paraganglioma","volume":"39","author":"Taieb","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/RLU.0000000000000475","article-title":"Bone and Lymph Node Metastases From Neuroblastoma Detected by (18)F-DOPA-PET\/CT and Confirmed by Posttherapy (131)I-MIBG But Negative on Diagnostic (123)I-MIBG Scan","volume":"39","author":"Demirsoy","year":"2014","journal-title":"Clin Nucl Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s00259-014-2691-0","article-title":"Prognostic Value of 18F-DOPA PET\/CT at the Time of Recurrence in Patients Affected by Neuroblastoma","volume":"41","author":"Piccardo","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-019-0484-y","article-title":"Concomitant 177lu-DOTATATE and Capecitabine Therapy in Malignant Paragangliomas","volume":"9","author":"Yadav","year":"2019","journal-title":"EJNMMI"},{"key":"B16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of Inoperable or Metastatic Paragangliomas and Pheochromocytomas With Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE","volume":"181","author":"Zandee","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B17","article-title":"(131)I-MIBG Treatment of Pheochromocytoma: Low Versus Intermediate Activity Regimens of Therapy","volume":"54","author":"Castellani","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"B18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/COC.0b013e31819e2c28","article-title":"Low-Dose Iodine-131 Metaiodobenzylguanidine Therapy for Patients With Malignant Pheochromocytoma and Paraganglioma Single Center Experience","volume":"33","author":"Shilkrut","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0b013e32834bad97","article-title":"[131i]Metaiodobenzylguanidine Therapy in Neural Crest Tumors: Varying Outcome in Different Histopathologies","volume":"32","author":"Rachh","year":"2011","journal-title":"Nucl Med Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1308992","article-title":"External Beam Radiation Therapy (EBRT) for Patients With Malignant Pheochromocytoma and Non-Head and -Neck Paraganglioma: Combination With 131I-MIBG","volume":"44","author":"Fishbein","year":"2012","journal-title":"Horm Metab Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"131i-MIBG Therapy for Malignant Paraganglioma and Phaeochromocytoma: Systematic Review and Meta-Analysis","volume":"80","author":"Van Hulsteijn","year":"2013","journal-title":"Clin Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0652-6","article-title":"[.Sup.131]I-MIBG Therapy in Metastatic Phaeochromocytoma and Paraganglioma","volume":"35","author":"Gedik","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/jso.24553","article-title":"Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the Management of Patients With Metastatic\/Progressive Phaeochromocytomas and Paragangliomas","volume":"115","author":"Nastos","year":"2017","journal-title":"J Surg Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.254987","article-title":"Addition Of 131i MIBG To PRRT (90y DOTATOC) For Personalized Treatment of Selected Patients With Neuroendocrine Tumors","volume":"62","author":"Bushnell","year":"2021","journal-title":"J Nucl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and Safety of High-Specific-Activity 131i-MIBG Therapy in Patients With Advanced Pheochromocytoma or Paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.778322\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T05:45:14Z","timestamp":1644212714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.778322\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":25,"alternative-id":["10.3389\/fendo.2022.778322"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.778322","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"article-number":"778322"}}